Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

Expert Opinion on Drug Discovery

Volumn 7, Issue 1, 2012, Pages 19-37

  D'Onofrio, Grazia ^a   Panza, Francesco ^a   Frisardi, Vincenza ^a   Solfrizzi, Vincenzo ^b   Imbimbo, Bruno P ^c   Paroni, Giulia ^a   Cascavilla, Leandro ^a   Seripa, Davide ^a   Pilotto, Alberto ^a,d  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

amyloid; Secretase inhibitors; Alzheimer's disease; Notch processing

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; BEGACESTAT; ELND 006; GAMMA SECRETASE INHIBITOR; MK 0752; NOTCH RECEPTOR; PF 3084014; SEMAGACESTAT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG RESEARCH; ENZYME INHIBITION; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; TRANSGENIC ANIMAL;

ALANINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AZEPINES; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS;

EID: 84855414394     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.645534     Document Type: Review

References (170)

1. Thies W, Bleiler L. Alzheimer's association. Alzheimer's disease facts and figures. Alzheimers Dement 2011;7:208-44
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91 (Pubitemid 46825511)
3. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
4. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27
5. Seripa D, Panza F, Franceschi M, et al. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Res Rev 2009;8:214-36
6. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8
7. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-7
8. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
9. Panza F, Solfrizzi V, Frisardi V, et al. Beyond the neurotransmitter- focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. Aging Clin Exp Res 2009;21:386-406
10. Frisardi V, Solfrizzi V, Imbimbo PB, et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res 2010;7:40-55
11. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702-16
12. Barten DM, Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008;37: 171-86
13. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-19
14. Panza F, Frisardi V, Imbimbo BP, et al. Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2010;2:767-82
15. Lannfelt L, Blennow K, Zetterberg H, et al. PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7: 779-86
16. Faux NG, Ritchie CW, Gunn A, et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional Phase II analyses. J Alzheimers Dis 2010;20:509-16
17. Ghosh AK, Gemma S, Tang J. Beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008;5:399-408 (Pubitemid 351952491)
18. Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 2011;11:1555-70
19. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother 2009;9:661-79
20. Panza F, Solfrizzi V, Frisardi V, et al. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009;26:537-55
21. Vellas B, Sol O, Snyder PJ, et al. EHT0202 in Alzheimer's disease: A 3-Month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011;8:203-12
22. McCarthy JV, Twomey C, Wujek P. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci 2009;66:1534-55
23. Guardia-Laguarta C, Pera M, Lleo A. gamma-Secretase as a therapeutic target in Alzheimer's Disease. Curr Drug Targets 2010;11:506-17
24. Haapasalo A, Kovacs DM. The many substrates of presenilin/gamma- secretase. J Alzheimers Dis 2011;25:3-28
25. Lleo A, Saura CA. gamma-secretase substrates and their implications for drug development in Alzheimer's disease. Curr Top Med Chem 2011;11:1513-27
26. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998;391:387-90 (Pubitemid 28093512)
27. Wolfe MS, Xia W, Ostaszewski BL, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999;398:513-17
28. Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaapp processing. Nature 2000;407:48-54
29. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006;96:732-42
30. Lleo A, Berezovska O, Growdon JH, Hyman BT. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 2004;12:146-56 (Pubitemid 38250298)
31. Panza F, Frisardi V, Imbimbo BP, et al. Review: gamma-Secretase inhibitors for the treatment of Alzheimer's disease: the current state. CNS Neurosci Ther 2010;16:272-84
32. Lleo A. Activity of gamma-secretase on substrates other than APP. Curr Top Med Chem 2008;8:9-16 (Pubitemid 351791042)
33. Petit A, Bihel F, Alves da Costa C, et al. New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat Cell Biol 2001;3:507-11 (Pubitemid 32422088)
34. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-16 (Pubitemid 33051236)
35. Sagi SA, Weggen S, Eriksen J, et al. The noncyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kB kinase, and NFkB, do not reduce amyloid-beta 42 production. J Biol Chem 2003;278:31825-30 (Pubitemid 37048364)
36. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J Clin Invest 2003;112:440-9 (Pubitemid 38063773)
37. Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid1-42 secretion. J Med Chem 2005;48:5705-20 (Pubitemid 41298345)
38. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004;10:1065-6 (Pubitemid 39424866)
39. Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003;278:18664-70 (Pubitemid 36799494)
40. Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005;11:545-50 (Pubitemid 40685978)
41. Czech C, Burns MP, Vardanian L, et al. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J Neurochem 2007;101:929-36 (Pubitemid 46683874)
42. Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gamma-secretase modulators. Nature 2008;453:925-9
43. Richter L, Munter LM, Ness J, et al. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci USA 2010;107:14597-602
44. Ohki Y, Higo T, Uemura K, et al. Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 2011; Epub ahead of print
45. Wolfe MS. Gamma-secretase modulators. Curr Alzheimer Res 2007;4:571-3
46. Peretto I, La Porta E. gamma-Secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr Top Med Chem 2008;8:38-46 (Pubitemid 351791045)
47. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science 2008;305:1119-23 (Pubitemid 39100316)
48. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 2008;17: 1005-13
49. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72 (Pubitemid 27019143)
50. Tomita T, Maruyama K, Saido TC, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997;94:2025-30 (Pubitemid 27113955)
51. Zhang Z, Nadeau P, Song W, et al. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2000;2:463-5
52. Armogida M, Petit A, Vincent B, et al. Endogenous beta-amyloid production in presenilin deficient embryonic mouse fibroblasts. Nat Cell Biol 2001;3:1030-3 (Pubitemid 34428750)
53. Wilson CA, Doms RW, Zheng H, Lee VM. Presenilins are not required for Ab42 production in the early secretory pathway. Nat Neurosci 2002;5:849-55 (Pubitemid 34976649)
54. Lai MT, Crouthamel MC, DiMuzio J, et al. A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage. J Neurochem 2006;96:118-25
55. Yagishita S, Futai E, Ishiura S. In vitro reconstitution of gamma-secretase activity using yeast microsomes. Biochem Biophys Res Commun 2008;377:141-5
56. Sevalle J, Ayral E, Hernandez JF, et al. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity. J Neurochem 2009;110:275-83
57. Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001;76:173-81 (Pubitemid 32044380)
58. Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88
59. Capell A, Grunberg J, Pesold B, et al. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J Biol Chem 1998;273:3205-11 (Pubitemid 28109729)
60. Yu G, Chen F, Levesque G, et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem 1998;273:16470-5 (Pubitemid 28311430)
61. Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 2000;407:48-54
62. Edbauer D, Winkler E, Haass C, Steiner H. Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. Proc Natl Acad Sci USA 2002;99:8666-71 (Pubitemid 34693617)
63. Chavez-Gutierrez L, Tolia A, Maes E, et al. Glu (332) in the nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity. J Biol Chem 2008;283:20096-105
64. Shah S, Lee SF, Tabuchi K, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005;122:435-47
65. Francis R, McGrath G, Zhang J, et al. Aph-1 and pen-2 are required for notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 2002;3:85-97 (Pubitemid 34778398)
66. Niimura M, Isoo N, Takasugi N, et al. Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions. J Biol Chem 2005;280:12967-75
67. Serneels L, Van Biervliet J, Craessaerts K, et al. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 2009;324:639-42
68. Shirotani K, Edbauer D, Prokop S, et al. Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem 2004;279:41340-5 (Pubitemid 39313572)
69. Hebert SS, Serneels L, Dejaegere T, et al. Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis 2004;17:260-72 (Pubitemid 39345781)
70. Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. J Neurosci 2005;25:192-8 (Pubitemid 40110780)
71. Serneels L, Dejaegere T, Craessaerts K, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA 2005;102:1719-24 (Pubitemid 40209234)
72. Lai MT, Chen E, Crouthamel MC, et al. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem 2003;278:22475-81 (Pubitemid 36830301)
73. Dejaegere T, Serneels L, Schafer MK, et al. Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc Natl Acad Sci USA 2008;105:9775-80 (Pubitemid 352031376)
74. Shirotani K, Tomioka M, Kremmer E, et al. Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes. Neurobiol Dis 2007;27:102-7 (Pubitemid 46921480)
75. Crystal AS, Morais VA, Pierson TC, et al. Membrane topology of gamma-secretase component PEN-2. J Biol Chem 2003;278:20117-23 (Pubitemid 36799206)
76. Bammens L, Chavez-Gutierrez L, Tolia A, et al. Functional and topological analysis of Pen-2, the fourth subunit of the gamma-secretase complex. J Biol Chem 2011;286:12271-82
77. Gu Y, Chen F, Sanjo N, et al. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. J Biol Chem 2003;278:7374-80 (Pubitemid 36800741)
78. Prokop S, Shirotani K, Edbauer D, et al. Requirement of PEN-2 for stabilization of the presenilin N-/Cterminal fragment heterodimer within the gamma-secretase complex. J Biol Chem 2004;279:23255-61 (Pubitemid 38685633)
79. Kim SH, Sisodia SS. A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1. J Biol Chem 2005;280:1992-2001
80. Sato T, Diehl TS, Narayanan S, et al. Active gamma-secretase complexes contain only one of each component. J Biol Chem 2007;282:33985-93 (Pubitemid 350159441)
81. Lazarov VK, Fraering PC, Ye W, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA 2006;103:6889-94
82. Ogura T, Mio K, Hayashi I, et al. Three-dimensional structure of the gamma-secretase complex. Biochem Biophys Res Commun 2006;343:525-34
83. Osenkowski P, Li H, Ye W, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol 2009;385:642-52
84. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22
85. Sestan N, Artavanis-Tsakonas S, Rakic P. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. Science 1999;286:741-6
86. Marambaud P, Wen PH, Dutt A, et al. A CBP binding transcriptional repressor produced by the PS1/gamma-cleavage of ncadherin is inhibited by PS1 FAD mutations. Cell 2003;114:635-45 (Pubitemid 37159259)
87. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-81 (Pubitemid 33150677)
88. Muller T, Meyer HE, Egensperger R, Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for alzheimer's disease. Prog Neurobiol 2008;85:393-406
89. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:2876-82
90. Milano J, McKay J, Dagenais C, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004;82:341-58 (Pubitemid 39485346)
91. Shih Ie M, Wang TL. Notch signaling, ô-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82
92. Lewis HD, Perez Revuelta BI, Nadin A, et al. Catalytic site directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Biochemistry 2003;42:7580-6 (Pubitemid 36735835)
93. Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity 2003;19:781-91 (Pubitemid 37542299)
94. Stanger BZ, Datar R, Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci USA 2005;102:12443-8 (Pubitemid 41266378)
95. Panelos J, Massi D. Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009;8:1986-93
96. Searfoss GH, Jordan WH, Calligaro DO, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003;278:46107-16 (Pubitemid 37432761)
97. Lathia JD, Mattson MP, Cheng A. Notch: from neural development to neurological disorders. J Neurochem 2008;107:1471-81
98. Costa RM, Honjo T, Silva AJ. Learning and memory deficits in Notch mutant mice. Curr Biol 2003;13:1348-54 (Pubitemid 36953310)
99. Wang Y, Chan SL, Miele L, et al. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci USA 2004;101:9458-62 (Pubitemid 38812896)
100. Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem 2008;8:17-33 (Pubitemid 351791043)
101. Li YM, Xu M, Lai MT, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000;405:689-94 (Pubitemid 30428655)
102. Esler WP, Kimberly WT, Ostaszewski BL, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2000;2:428-34
103. Imbimbo BP, Speroni F. beta-Amyloid Therapeutic Strategies for Alzheimer's Disease. In: Abraham DJ, editor. Burger's Medicinal Chemistry and Drug Discovery. 6th edition. John Wiley & Sons, Inc; Hoboken: 2005. p. 1-115
104. Comery TA, Martone RL, Aschmies S, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2005;25:8898-902 (Pubitemid 41384457)
105. Imbimbo BP. Alzheimer's disease: gamma-Secretase inhibitors. Drug Discov Today Ther Strateg 2008;5:169-75
106. Best JD, Jay MT, Otu F, et al. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 N2-(2S)-2-(3,5-difluorophenyl)-2- hydroxyethanoyl-N1-(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzob, dazepin-7-yl-L-alaninamide. J Pharmacol Exp Ther 2005;313:902-8 (Pubitemid 40604194)
107. Abramowski D, Wiederhold KH, Furrer U, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008;327:411-24
108. Garcia-Alloza M, Subramanian M, Thyssen D, et al. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener 2009;4:19
109. Gitter BD, Czilli DL, Li W, et al. A. Stereoselective inhibition of amyloid beta peptide secretion by LY450139 dihydrate, a novel functional gamma secretase inhibitor abstract P4-339. Neurobiol Aging 2004;25(Suppl 2):S571
110. Boggs LN, Fuson SF, Gitter BD, et al. In vivo characterization of LY450139, a novel, stereoselective, functional gamma-secretase inhibitor abstract P1-419. Neurobiol Aging 2004;25(Suppl 2):S218
111. May PC, Yang Z, Li W, et al. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice abstract O3-06-07. Neurobiol Aging 2004;25(Suppl 25):65
112. Lanz TA, Karmilowicz MJ, Wood KM, et al. Concentration-dependent modulation of Abeta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006;319:924-33
113. Cocke PJ, Boggs LN, Ness DK, May PC. Comparison of cisternal and lumbar cerebrospinal fluid amyloid beta concentrations following oral administration of LY450139 dihydrate to Beagle dogs abstract P1-017. Alzheimers Dement 2008;4(Suppl 2):T210
114. Ness DK, Boggs LN, Hepburn DL, et al. Reduced beta-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months abstract P2-053. Neurobiol Aging 2004;25(Suppl 2):S238
115. Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. Curr Opin Investig Drugs 2009;10:721-30
116. Bittner T, Fuhrmann M, Burgold S, et al. gamma-Secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci 2009;29:10405-9
117. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30:317-25 (Pubitemid 350307310)
118. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28:126-32 (Pubitemid 40923411)
119. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-4 (Pubitemid 43739900)
120. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-ecretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8
121. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009;66:48-54
122. ClinicalTrial.gov. Effect of LY450139 on the Long Term Progression of Alzheimer's Disease. Available from: http://clinicaltrials.gov/ct2/show/ NCT00594568?term=LY450139&rank=3 Last accessed 4 October 2011
123. ClinicalTrial.gov. Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2). Available from: http://clinicaltrials.gov/ct2/show/NCT00762411?term=LY450139&rank=2 Last accessed 4 October 2011
124. ClinicalTrial.gov. A Study of Semagacestat for Alzheimer's Patients (Identity XT). Available from: http://clinicaltrials.gov/ct2/show/NCT01035138? term=LY450139&rank=5 Last accessed 4 October 2011
125. Siemers ER. Update on the semagacestat program. 3rd Conference-Clinical Trials on Alzheimer's Disease; 3-5 November 2010;Toulouse
126. Ross JS, Imbimbo BP. Are gamma-secretase inhibitors detrimental for Alzheimer's disease patients? J Alzheimers Dis 2010;22:401-4
127. Martone RL, Zhou H, Atchison K, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009;331:598-608
128. Frick G, Raje S, Wan H, et al. GSI-953, a potent and selective gamma-secretase inhibitor-modulation of beta amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans abstract P4-366. Alzheimers Dement 2008;4(Suppl 2):T781
129. Wan H, Bard J, Martone R, et al. GSI-953, a potent and selective gamma-secretase inhibitor, modulates Abeta peptides in mice and humans: translating the PK/PD biomarker relationships in different biological compartments between rodent and human abstract P2-101. Alzheimers Dement 2008;4(Suppl 2):T548
130. Gillman KW, Starrett JE, Parker MF, et al. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med Chem Lett 2010;1:120-4
131. Gillman KW, Starrett JE, Parker MF, et al. BMS-708163, a potent and selective gamma-secretase inhibitor, decreases CSF Abeta at safe and tolerable doses in animals and humans abstract HT-01-05. 11th International Conference on Alzheimer's Disease (ICAD);26-31 July 2008;Chicago, IL, USA
132. Tong G, Castaneda L, Wang JS, et al. A study to evaluate the effects of single oral doses of BMS-708163 in the cerebrospinal fluid of healthy young men abstract O3-07-07. Alzheimers Dement 2010;6(Suppl 1):S143
133. Wang JS, Castaneda L, Sverdlov A, et al. A placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics (P) and pharmacodynamics (PD) of BMS-708163 in healthy young and elderly subjects abstract P3-303. Alzheimers Dement 2010;6(Suppl 1):S540
134. ClinicalTrial.gov. A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease. Available from: http://clinicaltrials.gov/ ct2/show/NCT00810147?term=NCT00810147&rank=1 Last accessed 4 October 2011
135. Salloway S, Coric V, Mark Brody M, et al. Safety and tolerability of BMS-708163 in a phase II study in mild-to-moderate Alzheimer's disease abstract O4-06-08. Alzheimers Dement 2011;7(Suppl 4):S695-6
136. Albright C, Andreasen N, Minthon L, et al. The gamma-secretase inhibitor BMS-708163 causes dose-dependent reductions in CSF Abeta40 levels in patients with mild-to-moderate Alzheimer's Disease (AD) abstract P2-015. Alzheimers Dement 2011;7(Suppl 4):S311
137. ClinicalTrial.gov. A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease. Available from: http://clinicaltrials.gov/ct2/show/ NCT00810147?term=BMS-708163&rank=6 Last accessed 4 October 2011
138. Kambhampaty A. Alzheimer's Disease Snapshot. BioPharm Insight; Kimberly Ha: 2011
139. Brigham E, Quinn K, Kwong G, et al. Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-beta concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration abstract P3-320. Alzheimers Dement 2010;6(Suppl 1):S546
140. Brigham E, Quinn K, Motter R, et al. Effects of single and multiple dose oral administration of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-beta concentrations in the brain and CSF of cynomolgus monkeys abstract P3-322. Alzheimers Dement 2010;6(Suppl 1):S546
141. Schroeter A, Brigham E, Motter R, et al. APP-selective gamma-secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid-beta in the PDAPP mouse model of Alzheimer's disease abstract P3-321. Alzheimers Dement 2010;6(Suppl 1):S546
142. Lanz TA, Wood KM, Richter KE, et al. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Ther 2010;334:269-77
143. Brodney M. Discovery of PF-3084014: a novel gamma-secretase inhibitor for the treatment of Alzheimer's disease abstract MEDI 233. 238th ACS National Meeting; 16-20 August 2009; Washington, DC
144. Qui R, Willavize S, Fullerion T, Gastonguay MR. Modeling and simulation of plasma Abeta in humans after multiple oral doses of Pf-3084014, a potent gamma-secretase inhibitor abstract P1-261. Alzheimers Dement 2009;5(Suppl 1):P253
145. ClinicalTrial.gov. A Trial In Patients With Advanced Cancer And Leukemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00878189? term=NCT00878189&rank=1 Last accessed 4 October 2011
146. Morimoto B. Drug Development for Neurodegenerative Diseases-a Marcus Evans Conference. IDdb Meeting Report; 7-8April 2009;Boston, MA
147. Rosen LB, Stone JA, Plump A, et al. The gamma-secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans Abstract O4-03-02. Alzheimers Dement 2006;2(Suppl 1):S79
148. Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006;24(Suppl 18):6585
149. Krop IE, Kosh M, Fearen I, et al. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol 2006;24(Suppl 18):10574
150. ClinicalTrial.gov. Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer. Available from: http://clinicaltrials.gov/ ct2/show/NCT00645333? term=NCT00645333&rank=1 Last accessed 4 October 2011
151. ClinicalTrial.gov. Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer. Available from:
152. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 2009;24:95-121
153. Xia X, Qian S, Soriano S, et al. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci USA 2001;98:10863-8 (Pubitemid 32878710)
154. He G, Luo W, Li P, et al. gamma-Secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010;467:95-8
155. Chen F, Hasegawa H, Schmitt-Ulms G, et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 2006;440:1208-12
156. Thathiah A, Spittaels K, Hoffmann M, et al. The orphan G protein-coupled receptor 3 modulates amyloidbeta peptide generation in neurons. Science 2009;323:946-51
157. Checler F, Dunys J, Pardossi-Piquard R, Alves da Costa C. p53 is regulated by and regulates members of the gamma-secretase complex. Neurodegener Dis 2010;7:50-5
158. Goodger ZV, Rajendran L, Trutzel A, et al. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci 2009;122:3703-14
159. Muller T, Meyer HE, Egensperger R, Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol 2008;85:393-406
160. Chang WP, Koelsch G, Wong S, et al. In vivo inhibition of Abeta production by memapsin 2 (betasecretase) inhibitors. J Neurochem 2004;89:1409-16 (Pubitemid 38802662)
161. Kim J, Onstead L, Randle S, et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci 2007;27:627-33 (Pubitemid 46143766)
162. Mitani T, Yarimizu J, Saita K, et al. Amelioration of Cognitive Deficits in APP Transgenic Mice with Subchronic Treatment of a gamma-Secretase Modulator but not Inhibitors poster 419. AD/PD 2011; Barcelona, Spain: 2011
163. Struble RG, Ala T, Patrylo PR, et al. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis 2010;22:393-9
164. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science 2010;330:198
165. Duce JA, Tsatsanis A, Cater MA, et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010;142:857-67
166. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46 (Pubitemid 47058377)
167. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9
168. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9
169. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92
170. Weiner MW, Aisen PS, Jack CR Jr, et al. Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010;6:202-11